Several studies [8–11] have serially monitored IGRA results in patients with rheumatic diseases receiving TNF-α antagonist therapy, but there are no standard recommendations for the timing of follow-up LTBI testing after the initial screening, how to interpret test results, and which patients should receive treatment based on subsequent results. Here, TNF is linked to rheumatic disorder.